Selective Androgen Receptor Modulator in a Patient With Hormone-Positive Metastatic Breast Cancer

Area of Science:

• Oncology
• Endocrinology

Background:

• Androgen receptors (ARs) are coexpressed in estrogen receptor (ER)-positive breast cancers, with their role in tumorigenesis not fully understood.
• Androgen-based therapies were previously explored but limited by toxicity and the advent of alternative treatments.
• Current research focuses on modulating the androgen pathway, particularly through AR inhibitors.

Observation:

• A case study investigated the use of a selective androgen receptor modulator (SARM) in a patient with heavily pretreated ER-positive breast cancer.
• The SARM was well-tolerated by the patient.

Findings:

• The patient achieved a durable partial response to the selective androgen receptor modulator therapy.
• This suggests a potential benefit of targeting the androgen pathway in this patient population.

Implications:

• Selective androgen receptor modulators represent a potential therapeutic strategy for ER-positive breast cancer, especially in heavily pretreated cases.
• Further research into androgen pathway modulation may yield novel treatments for breast cancer.
• This case highlights the potential of well-tolerated SARMs in managing advanced ER-positive breast cancer.